These cells also displayed greater aggressiveness in HER2-positive CRC in patient-derived tumor xenograft (PDX) models and showed potent immunotherapeutic capacity for CRC in metastatic xenograft mouse models (28). This evidence concerns the gene ERBB2 and colorectal carcinoma.